Home » Topics » Regulatory » EMA

EMA
RSS

CHMP issues positive opinion on European orphan drug status for darinaparsin in PTCL

Jan. 21, 2011

Abbott withdraws European MAA for Ozespa

Jan. 19, 2011

ChemGenex notifies EMA of withdrawal of MAA for Tekinex for Ph+ CML

Jan. 17, 2011

New indication for Lucentis in E.U. for vision loss in diabetic macular edema

Jan. 11, 2011

EMA and FDA grant expedited review for boceprevir

Jan. 11, 2011

Invega approved in E.U. for schizoaffective disorder

Jan. 7, 2011

EMA to review Allos' MAA for Folotyn in relapsed or refractory PTCL

Dec. 28, 2010

Novartis receives E.U. approval for Tasigna in newly diagnosed Ph+ CML

Dec. 27, 2010

CHMP recommends marketing authorization for Janssen-Cilag's Xeplion

Dec. 23, 2010

CHMP recommends a variation to marketing terms for Simponi

Dec. 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...